In patients with autoimmune rheumatoid diseases RA and SLE, anti-inflammatory biologic drugs, such as anti-TNF, anti-IL6, or anti-IL1β agents, can decelerate the atherogenic process [76]. The gene discussed is TNF; the disease is systemic lupus erythematosus.